Literature DB >> 6411830

Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.

G B Pier, D M Thomas.   

Abstract

Sera from humans vaccinated with a high-molecular-weight polysaccharide vaccine to Pseudomonas aeruginosa immunotype 1 (IT-1) were analyzed for duration of the immune response, specificity for the IT-1 determinant, and by assessing the immunoglobulin classes elicited. The ability of purified IgG, IgM, and IgA to interact with peripheral blood leukocytes, as well as purified polymorphonuclear neutrophils or mononuclear cells, was also examined in an opsonophagocytosis assay. Levels of antibody to IT-1 remained significantly (P less than 0.001) elevated 21 months after immunization. Responses were generally specific to the IT-1 serotype determinant. Some vaccinees also responded to immunotype 2 and immunotype 5 determinants. IgG, IgM, and IgA serum antibodies were all elicited by vaccination. IgG and IgA were effective opsonins for P aeruginosa. IgM-mediated opsonophagocytosis required complement. Serum IgA was highly effective in conjunction with mononuclear cells in opsonophagocytosis of P aeruginosa, suggesting that these immune components may be capable of protecting neutropenic hosts.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411830     DOI: 10.1093/infdis/148.2.206

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; T McVeigh; P Owen
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

2.  Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum.

Authors:  T R Anderson; T C Montie
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

Review 3.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

4.  Pseudomonas aeruginosa lipopolysaccharide: evidence that the O side chains and common antigens are on the same molecule.

Authors:  K Hatano; J B Goldberg; G B Pier
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

5.  Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.

Authors:  G B Pier; M Pollack; M Cohen
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

6.  Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.

Authors:  G Kronborg; A Fomsgaard; C Galanos; M A Freudenberg; N Høiby
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

7.  Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.

Authors:  P Ames; D DesJardins; G B Pier
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

Review 8.  Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.

Authors:  Gerald B Pier
Journal:  Int J Med Microbiol       Date:  2007-04-27       Impact factor: 3.473

9.  A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Terashima; I Uezumi; T Tomio; M Kato; K Irie; T Okuda; S Yokota; H Noguchi
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.

Authors:  G B Pier; D Thomas; G Small; A Siadak; H Zweerink
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.